CLOCK and chronic lung disease: Targeting multiple circadian clock molecules using selective agonists/antagonists (e.g., SR9009, and KL001) could be a novel approach for treating chronic lung disease associated with mesenchymal transition and abnormal ECM remodeling, such as COPD and lung fibrosis.